Skip to main content
Premium Trial:

Request an Annual Quote

GeneCentric Raises $5M

NEW YORK (GenomeWeb) – GeneCentric Diagnostics said in a document filed with the US Securities and Exchange Commission on Friday that it has raised $5 million in equity.

In an email to GenomeWeb Daily News, GeneCentric CEO Myla Lai-Goldman said the financing is the closing of the second tranche of the company's Series A financing round, and proceeds will go toward the continued development of its lead product called the Lung Subtype Platform. The company has raised $5.25 million to date, she said.

Based in Durham, NC, GeneCentric was launched in 2011 with funding from Hatteras Venture Partners. The company's technology is based on research carried out in the laboratories of Neil Hayes and Chuck Perou at the Lineberger Comprehensive Cancer Center at the University of North Carolina School of Medicine, according to Pharmacogenomics Reporter.

The Lung Subtype Platform is licensed to Laboratory Corporation of America Holdings and is available through its Integrated Oncology business as the HistoPlus Lung Cancer test. Lai-Goldman is the former chief medical officer and chief scientific officer of LabCorp.

In addition to the Lung Subtype Platform for stratifying lung cancer patients into subtypes, GeneCentric's other platform technology is Hypoxia Signature for identifying patients who respond to anti-angiogenesis therapies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.